Latest:
Refining EGFR Classifications and Impact on Treatment for NSCLC
Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale
Latest:
Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Benjamin Maughan, MD, PharmD
Latest:
Triple Combination Therapies in RCC: Clinical Trial Insights
Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Benjamin P. Levy, MD
Benjamin P. Levy, MD, is clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and associate professor of oncology at Johns Hopkins University School of Medicine.
Latest:
Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD
Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.
Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center
Latest:
Uncommon EGFR Mutations in NSCLC: Real-World Selection and Use of Novel Agents
Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, reflect on their experience managing real-world patients with uncommon EGFR mutations in non–small cell lung cancer.
Benjamin P. Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
Latest:
Uncommon EGFR Mutations in NSCLC: Future Directions in Care
Closing out their discussion on uncommon EGFR mutations in non–small cell lung cancer, Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, consider how the treatment paradigm will continue to evolve.
Benjamin P. Levy, MD, Sibley Memorial Hospital
Latest:
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Benjamin Powers, MD
Latest:
Focusing on Your Patient's Needs
Although the ever-expanding list of targeted drugs, and the seemingly relentless stack of evidence-based trials are daunting, the toughest yet most important lesson to me so far is to realize when doing everything is not warranted, necessary, desired, or feasible.
Benjamin R. Lee, MD
Latest:
Dr. Lee on Nanotechnology Combination Therapy in RCC
Benjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).
Benny Weksler, MD
Latest:
Dr. Weksler on Neoadjuvant and Adjuvant Therapy in NSCLC
Benny Weksler, MD, FACS, chief, Division of Thoracic Surgery, professor, Surgery, University of Tennessee Health Science Center, Eastridge-Cole Endowed Professor of Thoracic Surgery, West Cancer Center, discusses the role of minimally-invasive surgery in the stages of non–small cell lung cancers (NSCLC).